RxDoctor Payments Data

Zainab Ali, MD

Internal Medicine · Riverside, CANPI 1437449048

Payments from drug & device makers

$1,144in general payments, 2019–2025

Across 61 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$245
  • Boehringer Ingelheim$232
  • Novo Nordisk$146
  • Biohaven Pharmaceutical Holding Company Ltd.$95
  • GSK$74
  • Novartis$69
  • plus $283 from 8 others

What the payments were for

  • Food & beverage$1,144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,144 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$38,309
Medicare patients
159
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol194$134,352
JardianceEmpagliflozin127$98,078
JanuviaSitagliptin Phosphate115$79,459
TrulicityDulaglutide40$41,476
SynjardyEmpagliflozin/Metformin Hcl49$32,802
EliquisApixaban42$31,605
OzempicSemaglutide22$19,843
DapagliflozinDapagliflozin Propanediol25$13,795
MyrbetriqMirabegron20$13,334
Atorvastatin Calcium685$12,664
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,481
Metformin Hcl544$7,361
XareltoRivaroxaban12$6,688
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$5,875
Omega-3 Acid Ethyl Esters278$5,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$54$134,352194 claims
Boehringer IngelheimJardiance, Synjardy$232$130,880176 claims
MerckJanuvia$45$79,459115 claims
Novo NordiskOzempic$146$19,84322 claims
GSKTrelegy Ellipta$74$10,48116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →